Target intelligence / Profile preview

Keratin, type II cytoskeletal 2 epidermal (KRT2)

Target
KRT2
Molecular classification
Structural protein, Type II keratin, Intermediate filament protein, Cytoskeletal protein
01

Overview

Keratin, type II cytoskeletal 2 epidermal (KRT2) is a structural protein found predominantly in the upper spinous layer of epidermal keratinocytes, where it plays a critical role in the cytoskeleton and terminal differentiation of skin cells[1][3][2]. It is a member of the type II (basic or neutral) keratin family and forms heterodimers with type I keratins to assemble into intermediate filaments that maintain the integrity and resilience of epidermal tissue[4][6]. KRT2 expression is a hallmark of terminally differentiating suprabasal keratinocytes, especially in mechanically stressed epithelia such as the palms, soles, and other thick skin regions[2]. Mutations in KRT2 disrupt keratin filament structure, leading to epidermal fragility syndromes such as ichthyosis bullosa of Siemens and epidermolytic hyperkeratosis[1][3]. KRT2 is not considered a classic receptor, enzyme, or pharmacologic target, but its expression serves as a marker for keratinocyte differentiation and some skin pathologies[6][1].

Other names
Keratin 2Keratin 2AKeratin 2EKRT2AKRT2ECK-2eK2eKRTECytokeratin-2eEpithelial keratin-2eKeratin-2 epidermisKeratin-2eType-II keratin Kb2epidermal ichthyosis bullosa of Siemenskeratin 2, type IIKb2Krt2-17Krt2-2
02

Biological functions

Structural constituent of cytoskeletonStructural constituent of skin epidermisMaintenance of corneocytes and keratin filamentsContribution to terminal cornificationRegulation of keratinocyte differentiation and proliferationEstablishment of epidermal barrier, especially in thick skin
03

Disease associations

Skin disorders (notably ichthyosis bullosa of Siemens)Epidermolytic hyperkeratosisOther rare keratinopathies
04

Safety considerations

Mutations in KRT2 lead to skin fragility disorders (epidermolytic hyperkeratosis, ichthyosis bullosa of Siemens)Generally not a direct drug target, but loss/mutation can induce skin barrier defects
05

Biomarkers

Marker for differentiation status of suprabasal epidermal keratinocytesMay be used as a histopathological marker in some skin diseases

Beyond the preview

Go deeper on Keratin, type II cytoskeletal 2 epidermal (KRT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keratin, type II cytoskeletal 2 epidermal (KRT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call